RenovoRx, Inc.
Current role
RNXT
Leesa Gentry
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Leesa Gentry
RenovoRx, Inc. reported in an 8-K filed March 14, 2024 that Leesa Gentry was appointed Chief Clinical Officer, effective February 22, 2024. RenovoRx, Inc. reported in an 8-K filed February 23, 2024 that Leesa Gentry was appointed Chief Clinical Officer, effective March 1, 2024. The proxy statement of RenovoRx, Inc. reports total compensation of $890,151 for Leesa Gentry in fiscal 2024, including a base salary of $339,386. Disclosed compensation is on record for 2 fiscal years.
“on February 22, 2024, the board of directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”), appointed Leesa Gentry, the Company’s former Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company.”
“On February 22, 2024, the Company's board of directors (the "Board"), by unanimous written consent to action, appointed Leesa Gentry, the Company's current Senior Vice President of Clinical Operations, to the position of Chief Clinical Officer of the Company, effective March 1, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
RenovoRx, Inc. (RNXT)
Proxy statement
CurrentStart not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at RenovoRx, Inc.
Other people whose current roles at this company are on record from its filings.
- Shaun Bagai CEO, Board Member
- Shaun R. Bagai CEO, Board Member
- Ramtin Agah Chairman
- Ramtin Agah, M.D. Chairman
- James Ahlers CFO
- Mark Voll CFO
- Angela Gill Nelms COO
- Ronald B. Kocak Chief Accounting Officer
- Kirsten Angela Macfarlane Board Member
- Laurence J. Marton Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | RenovoRx, Inc. (RNXT) | Chief Clinical Officer | $339,386 | $890,151 |
| 2023 | RenovoRx, Inc. (RNXT) | Chief Clinical Officer | — | — |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.